mtm laboratories Announces the European Launch of CINtec(R) PLUS - Gilde Healthcare

mtm laboratories Announces the European Launch of CINtec(R) PLUS

8 maart 2010

Powerful new biomarker combination for cervical cancer screening 

mtm laboratories, a privately held diagnostics company today announced the launch of CINtec® PLUS, the company’s next generation cervical cancer screening product with unmatched accuracy for the screening and management for cervical cancer. CINtec® PLUS will be launched with claims direct in Germany, Italy, Spain, France and the UK, and will also be available in other parts of the world via mtm’s nominated distributors.*

CINtec® PLUS combines the p16 biomarker, widely validated for diagnostic purposes, with the proliferation marker Ki-67. By combining these two markers in a single diagnostic test, CINtec® PLUS provides both high sensitivity and high specificity for detecting high-grade cervical disease. The performance of this test for highly accurate detection of pre-cancerous cervical lesions has been demonstrated in three clinical trials conducted in over 30,000 women across Europe. In these studies, CINtec® PLUS was demonstrated to have significant clinical utility across a wide range of applications in cervical cancer screening and management.

“The combination of both high sensitivity and specificity in a single test is what sets CINtec® PLUS apart from currently available diagnostic tests”

said Robert Silverman, CEO of mtm laboratories,

“What this means for patients and clinicians is that early stage disease can be identified accurately in time for effective medical intervention. In comparison to the currently available technologies, CINtec® PLUS will minimize over or under diagnosis.”

CINtec® PLUS is the newest in a line of diagnostic and screening tests using the p16 biomarker that have been developed by mtm laboratories. CINtec® Histology and CINtec® Cytology are already marketed in Europe and were launched in 2007.
 
mtm laboratories AG is an ISO 9001 and ISO 13485 certified developer and manufacturer of In-Vitro Diagnostic Devices (IVDD) for use in the early detection and diagnosis of cervical cancer. The Company operates on a global basis with headquarters in Heidelberg, Germany and subsidiaries in the United States, France, Italy and Spain. Further information can be found at: www.mtmlabs.com

Gilde Healthcare invests alongside Capital A in Tromp Medical to accelerate international growth in the medical imaging market

Tromp Medical, Europe’s largest independent medical imaging sales and service organization, has attracted Gilde Healthcare as new investor to drive further growth in the medical imaging market. Headquartered in the Netherlands, Tromp Medical specializes in...
16 december 2024

Gilde Healthcare portfolio company SpliceBio Announces U.S. FDA IND Clearance of SB-007

SB-007 is the only IND-cleared, clinical-stage therapeutic addressing the root cause of Stargardt disease with the potential to treat all patients across all ABCA4 mutations Phase 1/2 ASTRA study set to begin in the first...
12 december 2024

Gilde Healthcare Portfolio Company Noema Pharma extends Series B financing round

Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, announced the successful close of a Series B extension financing round with an investment from EQT Life Sciences, bringing the total capital...
11 december 2024